Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-10-02
DOI
10.3389/fonc.2020.568809
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review
- (2019) Jean-Michel Lavoie et al. JOURNAL OF UROLOGY
- Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG Unresponsive Trials
- (2019) Max Kates et al. CLINICAL CANCER RESEARCH
- A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
- (2019) Amin H. Nassar et al. BRITISH JOURNAL OF CANCER
- The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
- (2019) Thomas Powles et al. CANCER TREATMENT REVIEWS
- Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette–Guérin Therapy
- (2018) Keishiro Fukumoto et al. ANNALS OF SURGICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma
- (2018) Tom Powles et al. Nature Reviews Urology
- Programmed death ligand‐1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder
- (2018) Bo Wang et al. CANCER SCIENCE
- Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer
- (2018) Viktoria Stühler et al. WORLD JOURNAL OF UROLOGY
- Clinical applications of PD-L1 bioassays for cancer immunotherapy
- (2017) Delong Liu et al. Journal of Hematology & Oncology
- Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Philippe E. Spiess et al. Journal of the National Comprehensive Cancer Network
- Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma
- (2017) Laura-Maria Krabbe et al. JOURNAL OF UROLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma
- (2017) Bo Zhang et al. MEDICAL ONCOLOGY
- Prognostic significance of PD-L1 in solid tumor
- (2017) Qianqian Wang et al. MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Biomarkers for immunotherapy in bladder cancer: a moving target
- (2017) David H. Aggen et al. Journal for ImmunoTherapy of Cancer
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
- (2015) J. Bellmunt et al. ANNALS OF ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma
- (2015) Sheila F. Faraj et al. UROLOGY
- PD-L1 and Survival in Solid Tumors: A Meta-Analysis
- (2015) Pin Wu et al. PLoS One
- Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance
- (2010) Yonghua Wang et al. Journal of Huazhong University of Science and Technology-Medical Sciences
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started